[3]. RedHill s key clinical late-stage investigational development programs include: (i)
RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii)
opaganib (Yeliva
-in
-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii)
RHB-104, with positive results from a first Phase 3 study for Crohn s disease; (iv)
RHB-102 (
Bekinda
®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v)
RHB-107 (
upamostat), a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is also being evaluated for COVID-19 and (vi)
Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund FBJ jumped 4% by the afternoon, while the Defiance Nasdaq Junior Biotechnology ETF IBBJ,
-1.01% and the SPDR S&P Biotech ETF XBI,
-0.01% both gained 3.5%. The VanEck Vectors Biotech ETF BBJ, gained 2.7%, and the Global X Genomics & Biotechnology ETF GNOM,
+1.29% was 2.3% higher on Monday but has gained the most - 56% - in the year to date among the funds noted here. FactSet data show that among all U.S. domiciled ETFs, the Van Eck fund has the most exposure to Alexion